Commodore Capital LP Mersana Therapeutics, Inc. Transaction History

Commodore Capital LP

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 14, 2023	BUY	$1.06 - $3.91 $2.38 Million - $8.78 Million	2,244,378 New	2,244,378 $2.85 Million
Q3 2021 Nov 15, 2021	SELL	$8.56 - $14.47 $3.67 Million - $6.21 Million	-429,228 Closed	0 $0
Q1 2021 May 17, 2021	BUY	$15.31 - $26.52 $4.14 Million - $7.17 Million	270,401 Added 170.25%	429,228 $6.95 Million
Q4 2020 Feb 16, 2021	BUY	$16.84 - $27.59 $2.67 Million - $4.38 Million	158,827 New	158,827 $4.23 Million

121

116M

233K

457K

Ticker MRSN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 97,169,296
Market Cap $216M
Description
Mersana Therapeutics, Inc., a clinical stage biopharmaceutical company, develops antibody drug conjugates (ADC) for cancer patients with unmet need. It develops XMT-1592, a Dolasynthen ADC targeting NaPi2b-expressing tumor cells, which is in phase I clinical trial for the treatment of ovarian cancer and NSCLC adenocarcinoma. The company also dev...

Get notified when there are updates to the investment portfolio of Commodore Capital LP, based on Form 13F filings with the SEC.

Stay updated on Commodore Capital LP with notifications on news.